Khavinson BioregulatorTarget: Blood vesselsCardiovascular

Vesugen

Lys-Glu-Asp · KED · Vascular Bioregulator · Везуген

Vesugen is synthetic Lys-Glu-Asp (KED), the endothelial cytogen. Ventfort is the vessel Cytomax complex. KED is not Crystagen and not a nitric-oxide donor drug.

Not FDA-approved - research chemical
Reviewed by CalcMyPeptide Editorial Team
Last updated: August 2026Evidence: Low4 peer-reviewed citations
Typical research dose
1–2 capsules/day (Cytomed) or 1–2 mg SC (research vial)
Frequency
1× daily for 10-30 day cycles
Half-life
Short (tripeptide)
Common vials
5 mg / 10 mg
CAS
N/A
Molecular weight
436.43 g/mol

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

  • Longevity / aging3.5/10

    Khavinson-school tissue peptide. Single-lab concentration after haircut. Not a Western Phase 3 geroprotector.

Compound card

Sequence
KED
Class
Khavinson cytogen (KED)
Formula
C17H28N4O9
Status
Not FDA-approved · research use
Dose it
5 mg + 2.5 mL BAC water → 2 mg/mL · 1000 mcg ≈ 50 units (U-100)
Open in calculator

How it works

Vesugen (Lys-Glu-Asp) is a tripeptide bioregulator targeting vascular endothelial cell gene expression. It promotes endothelial function restoration, reduces arterial stiffness, and supports angiogenic signaling. Khavinson studies show improved vascular markers, endothelial function, and cardiovascular biomarkers in aging animals and humans.

Source: PMID: 15677927

Khavinson map

Canonical 41
Class
Cytogen (synthetic short peptide)
Organ
Blood vessels / endothelium
Target
Blood vessels
System
Cardiovascular
Sequence
KED · Lys-Glu-Asp
Pair
Ventfort (vessel Cytomax)
Везуген

Used in bioregulator stacks

Manufacturer-style organ combinations - not FDA protocols. Every name is a live leaf.

The Khavinson school

Vladimir Khatskelevich Khavinson (1946–2024) spent five decades at what became the St. Petersburg Institute of Bioregulation and Gerontology arguing a simple, stubborn idea: aging is, in part, a failure of tissue-specific peptide signals, and those signals can be restored. The first products were not “peptides” in the Instagram sense. They were Cytamins - polypeptide fractions isolated from a named organ of young animals. Later commercial refinements of those fractions are sold as Cytomaxes (Cytomed / NPCRIZ): still mixtures, still oral capsules, still defined by the source organ rather than a single sequence. When the group identified short active motifs inside those mixtures, they synthesized them as Cytogens - di-, tri-, and tetrapeptides with a one-letter code (KE, AEDG, KED, EDR, KEDP, and so on).

That three-layer stack is the whole map. Cytamin / pharmaceutical extracts (Thymalin, Epithalamin, Cortexin, Retinalamin, Prostatilen) are the clinic-era injectables registered in the former Soviet pharmacopeia. Cytomaxes are the capsule complexes Cytomed still lists as a 21-SKU organ line. Cytogens are the defined synthetics. English-language educators, including Brenden Henry’s public writing at Peptide Science Institute, add a further commercial distinction - later analog SKUs (N-acetyl, amidate, “V2” complexes) sold as more stable or more diverse than the original Cytomed lots. That last layer is a product taxonomy, not a Khavinson paper. We describe it so readers are not gaslit by three bottles with the same organ name. We do not reproduce paid Peptide Mastery protocols, Precision Cell Method language, or anyone else’s course IP.

Full Cytamin → Cytomax → Cytogen map, literature limits, and how we counted 41

The mechanism Khavinson published is epigenetic, not receptor-agonist in the GLP-1 sense. Short peptides are claimed to enter nuclei, interact with DNA/histones, and reopen tissue-specific transcription that condensed with age (heterochromatin → euchromatin). Reviews in the Bulletin of Experimental Biology and Medicine and Neuroendocrinology Letters (PMID 14523363, 15677927, 23888677) are the citable core. Complementary GI pharmacology is not mystical: di- and tripeptides are PEPT1/LAT substrates, which is why oral capsules are even a conversation. What is not established in Western Phase 3 programs is organ-by-organ disease treatment, telomere reversal as a clinical endpoint, or the manufacturer claim that Cytomax is “a third stronger” than Cytogen. Those are NPCRIZ marketing sentences.

Khavinson’s group published hundreds of papers, many in Russian, many in the same journal family. That is a real literature. It is also a literature with limited independent Western replication, small n, and a habit of using one review PMID as a stamp on every organ. On this site a leaf earns its organ story, its Cytomax↔Cytogen pair, its sequence if it has one, and an honest sentence about what has not been shown. Reconstitution math belongs on cytogens sold as vials. Cytomax capsules do not get a fake 5 mg vial.

The 41 we treat as canonical are the 21 Cytomaxes on the public e-peptide/Cytomed list, the 12 Cytogens on that same commercial line (including Vesilut, which Western catalogs often drop), plus eight historically load-bearing molecules that sit beside the capsule SKUs: Epitalon, Vilon, Thymogen, Livagen, Cortagen, Prostamax, Thymalin, and Epithalamin. Honluten, Cortexin, Retinalamin, Prostatilen, Thymulin, N-acetyl-epitalon-amidate, Pinalex, and the GPL Man / GPL Femme kits are covered as adjacent - same school or same storefront, not padded into a fake 41.

Public English-language teaching (including Brenden Henry at peptidescienceinstitute.com) is cited as context, not copied. Paid Peptide Mastery / Peptide Salvation text stays theirs.

History of this molecule

KED is one of the cleaner sequence stories in this catalog: three residues, vessel cells, Cytomed cytogen line. The claim family is endothelial gene expression, capillary trophism, and the unglamorous work of keeping the lining of the pipe from senescing. Sales copy that says it “reverses atherosclerosis” is stealing statin/PCSK9 language.

Do not file Vesugen next to BPC-157 just because both get sold as “vascular.” BPC is a gastric pentadecapeptide with angiogenesis-adjacent animal data. Vesugen is a Khavinson tripeptide in the organ-identity model.

Chelohart/Cardiogen are myocardium. Vesugen is not a heart-failure drug.

Caveats

A defined sequence is not an FDA indication. Vascular cytogens sit in a Russian experimental-gerontology literature with limited Western replication. “Oral bioavailability because PEPT1” is real peptide-transport biology; it is not proof this SKU treats the organ disease. Gray-market identity is a live problem - HPLC is the only way to know the vial is the sequence on the label.

Full 41-map: Khavinson bioregulators index · Bioregulator stacks

Research Use Cases

  • ✓KED identity vs Ventfort vs Cardiogen
  • ✓Not an atherosclerosis or endothelial-restoration protocol

Dosing

PhaseDoseFrequencyNotes
Khavinson Protocol1–2 capsules/day or 1–2 mg SCDaily for 10–30 day courses, 1-2x per yearVascular bioregulator. Often paired with Chelohart (cardiac) for comprehensive cardiovascular aging support.

Administration

Route / form
Two real SKUs: Cytomed oral capsules (swallowed) or a lyophilized research vial reconstituted for subcutaneous injection. Nobody manufactures these as sublingual tablets.
Timing
Capsules: morning, about 30 minutes before meals. Research vial (SubQ): food does not change the injection.
Empty stomach?
Capsules: yes - Swallow on an empty stomach, about 30 minutes before meals. Reconstituted vial (SubQ): food does not change the injection. Cytomed boxes sometimes print “with food” because they are labeled as supplements; the manufacturer user-guide preference is before meals.

Vesugen: oral vs SubQ

Cytomed oral capsule
Bioavailability
No published human F% for this SKU. Di- and tripeptides can ride PEPT1/LAT; that is transporter biology, not proof the capsule treats the named organ. Cytomed cytogen capsules are swallowed.
Dose note
Vesugen Cytomed cytogen capsules: 1–2 capsules/day, typically 10–30 day courses. No reconstitution. Swallow; do not melt under the tongue. Swallowed with water. Morning, about 30 minutes before meals, is manufacturer user-guide folklore. Cytomed boxes sometimes print “with food” because they are labeled as supplements. That is not a published absorption RCT for this SKU. Pair: Ventfort is the vessel Cytomax. Cardiogen (AEDR) is myocardium. Chelohart is the heart complex.
Advantages
  • Official Cytomed cytogen SKU is a swallowed capsule. No BAC water, no syringe.
  • Matches how Cytomed ships the poster line.
  • Nobody manufactures this as a sublingual tablet.
  • KED is one of the cleaner sequence stories on the poster: three residues, vessel cells, Cytomed cytogen line.
Considerations
  • Capsule milligrams are not 1–2 mg SC. Do not convert a research-vial protocol into capsule counts by arithmetic theater.
  • Empty-stomach timing is user-guide folklore plus PEPT1 logic, not a cited human PK study for this SKU.
  • Vesugen is KED endothelium. It is not Crystagen (EDP immune), not Cardiogen (heart muscle), not a nitric-oxide donor drug, and not Vesilut (bladder).
  • Keep the ACE inhibitor until a clinician says otherwise. A capsule is not a blood-pressure drug.
Research vial SubQ
Bioavailability
No published human PK curve for this cytogen. Research-chem SubQ is the gray-market route. Class estimate is minutes-to-hours, not a depot ester.
Dose note
Research lyophilized vial: reconstitute with bacteriostatic water, sterile technique, SubQ. Class pattern is about 1–2 mg daily for on the order of 10 days, not a 12-week GLP-1 titration. Food does not change the injection. Do not convert Cytomed capsule counts into vial milligrams. Pair: Ventfort is the vessel Cytomax. Cardiogen (AEDR) is myocardium. Chelohart is the heart complex.
Advantages
  • Vial math is checkable if the COA matches the sequence on the label.
  • Food timing is irrelevant for SubQ.
  • Short pulsed courses match how the school used defined synthetics.
Considerations
  • Gray-market identity: HPLC is the only way to know the cake is KED (Lys-Glu-Asp).
  • Not a Western Phase 3. Russian experimental-gerontology literature is real and concentrated.
  • Not a sublingual tablet and not a Cytomax complex.
  • Vesugen is KED endothelium. It is not Crystagen (EDP immune), not Cardiogen (heart muscle), not a nitric-oxide donor drug, and not Vesilut (bladder).
  • eNOS-upregulation marketing is a mechanism hypothesis, not a nebivolol or statin equivalent. No MACE endpoint trial.
Recommendation: Two SKUs. Swallow Cytomed Vesugen capsules (no recon, not sublingual) or BAC-reconstitute a research vial for SubQ at the 1–2 mg / ~10-day class pattern. Food does not change the shot. Pair: Ventfort is the vessel Cytomax. Cardiogen (AEDR) is myocardium. Chelohart is the heart complex. Vesugen is KED endothelium. It is not Crystagen (EDP immune), not Cardiogen (heart muscle), not a nitric-oxide donor drug, and not Vesilut (bladder). Russian literature is real; Western Phase 3 is not. Endothelium is not myocardium. One letter off Crystagen is a different peptide.

Timeline

Day 1-10 (course)
Vascular endothelial gene expression restoration initiated.
Month 3-6
Improved endothelial function markers and arterial stiffness with repeat courses.

Who it is for

Vascular Aging / Endothelial Health

Low

Vascular endothelial bioregulator. Targets age-suppressed endothelial gene expression.

Reconstitution

VialWaterConcentrationExample dose
Lyophilized cytogen (if the SKU is a vial)Follow the COA fillDo the mathCapsules skip this step. Cytomax complexes are not this molecule.

Change vial size or water volume? Open the reconstitution calculator.

Safety & Considerations

Research peptide. Extensively used in Russian clinical protocols. Russian clinic history is not a US safety NDA.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

  • A defined sequence is not an FDA indication.
  • Gray-market identity is a live problem. HPLC beats a blog table.
  • Do not paste a sibling cytogen’s papers onto this SKU.
  • This site will not treat the named organ disease from a peptide page.

Verdict

Vesugen is the synthetic KED cytogen for Blood vessels / endothelium. Khavinson’s group published in this family. That is a concentrated literature, not a Western Phase 3. Capsules and vials are different SKUs.

Interactions & Contraindications

This site will not treat vascular disease from a peptide page.

Synergies & Common Stacks

+ Ventfort →

Cytogen vs Cytomax. Not a combo RCT.

Frequently Asked Questions

Vesugen vs Ventfort vs Cardiogen?▼
Vesugen = KED cytogen (vessels). Ventfort = vessel Cytomax. Cardiogen = heart cytogen. Endothelium ≠ myocardium.
Oral capsule or injection?▼
Two SKUs. Cytomed Vesugen is a swallowed cytogen capsule (1–2/day, typical 10–30 day courses, morning empty-stomach folklore, no reconstitution, not a sublingual tablet). Research vials are BAC-reconstituted SubQ at about 1–2 mg for on the order of 10 days; food does not change the shot. KED endothelium, not Crystagen, not Cardiogen, not Vesilut.
Blood pressure drug?▼
Not labeled. Keep the ACE inhibitor until a clinician says otherwise.
Same as Crystagen?▼
No. Crystagen is EDP immune. Vesugen is KED vessels. One letter off is a different peptide.
How does Vesugen differ from other cardiovascular peptides?▼
Vesugen targets vascular endothelial cell gene expression, reversing epigenetic aging of the vessel wall. Unlike acute vasodilators (VIP), Vesugen works at the transcriptional level for long-term endothelial restoration.

References

  1. Khavinson VKh et al. “Tissue-specific effects of peptides.” Bulletin of Experimental Biology and Medicine (2005). PMID: 15677927
  2. Khavinson VKh, Lin’kova NS, Tarnovskaya SI “Short peptides regulate gene expression.” Bulletin of Experimental Biology and Medicine (2013). PMID: 23888677
  3. Khavinson VKh, Morozov VG “Peptide regulation of aging: from experimental studies to clinical practice.” Advances in Gerontology (2003). PMID: 14523363
  4. Khavinson VKh et al. “"Short peptide bioregulators for vascular aging".” Bulletin of Experimental Biology and Medicine (2009). PMID: 19503960

📚 Related Articles

Epitalon: The Science of Telomerase Activation, Khavinson's Legacy, and Longevity Peptides
14 min read • Longevity
Recommended sourceOral bioregulator

Get Vesugen from Vita-Stream - a distributor for Khavinson-line oral capsules. No reconstitution math on a Cytomax bottle.

Browse VesugenSee all sources →

Affiliate link · Full review

← Back to Peptide Library·Bioregulator stacks